Proposal of recommended experimental protocols for <i>in vitro</i> and <i>in vivo</i> evaluation methods of boron agents for neutron capture therapy
-
- Yoshihide Hattori
- Research Center for BNCT, Osaka Metropolitan University , 1-1 Gakuen-cho, Nakaku, Sakai 599-8531 , Japan
-
- Tooru Andoh
- Laboratory of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Kobe Gakuin University , Kobe 650-8586 , Japan
-
- Shinji Kawabata
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686 , Japan
-
- Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686 , Japan
-
- Hiroyuki Michiue
- Neutron Therapy Research Center, Okayama University , 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558 , Japan
-
- Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology , 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503 , Japan
-
- Takahiro Nomoto
- Department of Life Sciences , Graduate School of Arts and Sciences, , 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902 , Japan
-
- Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University , 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
-
- Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University , 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
-
- Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University , 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
-
- Tsubasa Watanabe
- Institute for Integrated Radiation and Nuclear Science, Kyoto University , 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
-
- Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686 , Japan
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Recently, boron neutron capture therapy (BNCT) has been attracting attention as a minimally invasive cancer treatment. In 2020, the accelerator-based BNCT with L-BPA (Borofalan) as its D-sorbitol complex (Steboronine®) for head and neck cancers was approved by Pharmaceutical and Medical Devices Agency for the first time in the world. As accelerator-based neutron generation techniques are being developed in various countries, the development of novel tumor-selective boron agents is becoming increasingly important and desired. The Japanese Society of Neutron Capture Therapy believes it is necessary to propose standard evaluation protocols at each stage in the development of boron agents for BNCT. This review summarizes recommended experimental protocols for in vitro and in vivo evaluation methods of boron agents for BNCT based on our experience with L-BPA approval.</jats:p>
収録刊行物
-
- Journal of Radiation Research
-
Journal of Radiation Research 64 (6), 859-869, 2023-09-16
Oxford University Press (OUP)